Thinly traded Organogenesis (ORGO +7.7%) is up on light volume in early trade following its Q2 report released this morning. Highlights:
Revenue: $64.9M (+49%); Advanced Wound Care: $55.2M (+50%); Surgical & Sports Medicine: $9.7M (+46%).
PuraPly sales: $29.7M (+133%).
Net loss: ($9.6M); loss/share: ($0.11).
2019 guidance: Revenue: $250M – 262M from $249M – 262M; Advanced Wound Care: $219M – 224M; Surgical & Sports Medicine: $31M – 38M; PuraPly: $110M – 120M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.